Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00770471
Other study ID # NABTT-0801 CDR0000616542
Secondary ID U01CA062475ABTC-
Status Completed
Phase Phase 1
First received
Last updated
Start date July 13, 2009
Est. completion date March 1, 2012

Study information

Verified date June 2018
Source Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with radiation therapy and temozolomide may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of ABT-888 when given together with radiation therapy and temozolomide and to see how well it works in treating patients with newly diagnosed glioblastoma multiforme.


Description:

OBJECTIVES:

Primary

- To determine the maximum tolerated dose (MTD) of ABT-888 when administered in combination with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma multiforme. (Phase I)

- To estimate the overall survival of patients treated with ABT-888 when administered at the MTD in combination with radiotherapy and temozolomide. (Phase II)

Secondary

- To assess the toxicity associated with this regimen. (Phase I)

- To assess and describe the pharmacokinetics of ABT-888. (Phase I)

- To estimate the frequency of toxicity associated with this regimen. (Phase II)

OUTLINE: This is a multicenter, phase I dose-escalation study of ABT-888 followed by a phase II study.

- Initiation therapy: Patients receive oral ABT-888 twice daily (once on day 1 only) and oral temozolomide once daily (beginning on day 2) in weeks 1-6. Patients enrolled in the phase I dose-escalation/phase II portion of the study also undergo concurrent radiotherapy once daily 5 days a week (beginning on day 2) in weeks 1-6. Treatment continues in the absence of disease progression or unacceptable toxicity.

- Maintenance therapy: Beginning 4 weeks after completion of initiation therapy, patients receive oral ABT-888 twice daily on days 1-7 and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 4 courses (6 courses for patients enrolled in the phase I dose-escalation/phase II portion of the study) in the absence of disease progression or unacceptable toxicity.

Blood samples are collected periodically for pharmacokinetic, pharmacogenetic, and pharmacodynamic analysis. Samples are analyzed for concentration of ABT-888 in plasma by reversed-phase isocratic high performance liquid chromatography with electrospray ionization mass spectrometry; identification of novel markers of treatment response by plasma proteomic evaluation; DNA methylation and/or mutation; and PARP inhibition by ELISA.

After completion of study therapy, patients are followed every 2 months.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date March 1, 2012
Est. primary completion date March 1, 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme)

- Newly diagnosed disease

- Patients enrolled in the phase I initial safety portion of the study must meet the following additional criteria:

- Received 90% of planned radiotherapy and = 80% of planned concurrent temozolomide within the past 28-49 days

- No grade 3-4 toxicity attributed to temozolomide

- Has undergone gadolinium MRI or contrast CT scan within the past 28 days

- Patients enrolled in the phase I dose-escalation/phase II portion of the study must meet the following additional criteria:

- Recovered from immediate post-operative period and maintained on a stable corticosteroid regimen (no increase in 5 days) prior to starting study treatment

- Has undergone gadolinium MRI or contrast CT scan within the past 14 days

PATIENT CHARACTERISTICS:

- Karnofsky performance status 60-100%

- Life expectancy = 3 months

- ANC = 1,500/mm^3

- Platelet count = 100,000/mm^3

- Hemoglobin = 9.0 g/dL

- Creatinine = 2.0 mg/dL OR creatinine clearance = 60 mL/min

- Total bilirubin = 1.5 mg/dL

- Transaminases = 2.5 times upper limit of normal

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception prior to, during, and for 3 months after completion of study therapy

- Mini Mental State Exam score = 15

- Able to swallow and retain oral medications

- No concurrent serious infection or medical illness that would jeopardize the ability of the patient to receive study treatment with reasonable safety

- No other malignancy within the past 5 years except for curatively treated carcinoma in situ or basal cell carcinoma of the skin

- No known uncontrolled seizure disorder (i.e., status epilepticus) or seizures occurring = 3 times per week over the past month

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- More than 10 days since prior cytochrome P450-inducing anticonvulsants (e.g., phenytoin, carbamazepine, phenobarbital, primidone, or oxcarbazepine)

- At least 1 week since prior biopsy or resection of tumor (for patients enrolled in the phase I dose-escalation/phase II portion of the study)

- No prior radiotherapy, chemotherapy, immunotherapy, hormonal therapy, or biological therapy (including immunotoxins, immunoconjugates, antisense therapy, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy) for treatment of brain tumor (for patients enrolled in the phase I dose-escalation/phase II portion of the study)

- Prior glucocorticoid therapy allowed

- No other prior chemotherapy or investigational agents (for patients enrolled in the phase I initial safety portion of the study)

- Prior Gliadel wafers allowed (for patients enrolled in the phase I portion of the study)

- No prior Gliadel wafers (for patients enrolled in the phase II portion of the study)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
temozolomide

veliparib

Genetic:
DNA methylation analysis

gene expression analysis

mutation analysis

proteomic profiling

Other:
high performance liquid chromatography

immunoenzyme technique

laboratory biomarker analysis

mass spectrometry

pharmacogenomic studies

pharmacological study

Procedure:
adjuvant therapy

Radiation:
radiation therapy


Locations

Country Name City State
United States Winship Cancer Institute of Emory University Atlanta Georgia
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States UAB Comprehensive Cancer Center Birmingham Alabama
United States Massachusetts General Hospital Boston Massachusetts
United States Cleveland Clinic Taussig Cancer Center Cleveland Ohio
United States Josephine Ford Cancer Center at Henry Ford Hospital Detroit Michigan
United States University of Wisconsin Comprehensive Cancer Center Madison Wisconsin
United States Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania
United States UPMC Cancer Centers Pittsburgh Pennsylvania
United States UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California
United States Wake Forest University Comprehensive Cancer Center Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose of ABT-888 (Phase I) continous
Primary Overall survival (Phase II) continous
Secondary Toxicity (Phase I) continous
Secondary Pharmacokinetics of ABT-888 (Phase I) continous
Secondary Frequency of toxicity (Phase II) continous
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma Phase 2
Recruiting NCT00887146 - Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00621686 - Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Terminated NCT00227032 - Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme Phase 1
Terminated NCT00243022 - Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00278278 - Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Phase 3
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Completed NCT00416819 - Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma N/A
Completed NCT00052286 - Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer N/A
Completed NCT00006093 - EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT00004129 - Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Phase 1
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003417 - Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00008008 - Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Phase 2
Completed NCT00003464 - Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Completed NCT00003020 - LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases Phase 1